Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

By sjmartinez • March 21, 2024

Yuen MF, Fung S, Ma X, Nguyen TT, Hassanein T, Hann HW, Elkhashab M, Nahass RG, Park JS, Jacobson IM, Ayoub WS, Han SH, Gane EJ, Zomorodi K, Yan R, Ma J, Knox SJ, Stamm LM, Bonacini M, Weilert F, Ramji A, Bennett M, Ravendhran N, Chan S, Dieterich DT, Kwo PY, Schiff ER, Bae HS, Lalezari J, Agarwal K, Sulkowski MS. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses. JHEP Rep. 2024 Jan 18;6(4):100999. doi: 10.1016/j.jhepr.2023.100999. PMID: 38510983; PMCID: PMC10951643.

Tags: Antiviral, Cedars Sinai DoM, Core inhibitor, Digestive Diseases, Hepatitis, hepatitis B virus, Nucleos(t)ide reverse transcriptase inhibitor, Off-treatment, Open-label, Publications, Viral relapse

Increased mortality from alcohol use disorder, alcohol-associated liver disease, and liver cancer from alcohol among older adults in the United States: 2000 to 2021

Danpanichkul P, Duangsonk K, Tham EKJ, Tothanarungroj P, Auttapracha T, Prasitsumrit V, Sim B, Tung D, Barba R, Wong RJ, Leggio L, Yang JD, Chen[...]

A Promising Pathway Toward Mitigation and Eradication of Coronary Artery Disease

Karlsberg RP, Cho GW, Aldana-Bitar J. A Promising Pathway Toward Mitigation and Eradication of Coronary Artery Disease. Cardiol Res. 2024 Dec;15(6):415-424. doi: 10.14740/cr1721. Epub 2024[...]

2024 Update of the RECOVER-Adult Long COVID Research Index

Geng LN, Erlandson KM, Hornig M, Letts R, Selvaggi C, Ashktorab H, Atieh O, Bartram L, Brim H, Brosnahan SB, Brown J, Castro M, Charney[...]